Anbio Biotechnology Announces Closing of Initial Public Offering

Key Takeaways:

• Anbio Biotechnology closed an $8 million IPO and began trading on Nasdaq.
• Shares trade under the ticker symbol “NNNN” since February 19, 2025.
• Proceeds will support expansion, R&D, and corporate operations.
• Anbio offers diverse diagnostic platforms across critical medical fields.
• The company aims to transform diagnostics with personalized solutions.

Anbio Biotechnology Debuts on Nasdaq with $8 Million IPO

Anbio Biotechnology, a global diagnostic company dedicated to advancing medical technology and providing in vitro diagnostics (IVD) products, announced the closing of its initial public offering (IPO) of 1,600,000 Class A ordinary shares. Priced at US$5.00 per share, the offering resulted in aggregate gross proceeds of US$8 million before deducting underwriting discounts and related expenses.

Trading Under ‘NNNN’ on Nasdaq

On February 19, 2025, Anbio’s Class A ordinary shares began trading on the Nasdaq Global Market under the ticker symbol “NNNN”. This milestone marks a significant step for the Frankfurt-based company, enhancing its visibility and accessibility to investors worldwide.

Fueling Expansion and Innovation

The proceeds from the offering are earmarked for strategic expansion of Anbio’s sales and distribution network in selected markets, bolstering research and development efforts, and supporting working capital and general corporate purposes.

“Transforming Diagnostics Globally”

“By prioritizing innovation, affordability, and speed, we aim to transform the global diagnostics landscape,” the company stated. Anbio is committed to fostering a paradigm shift towards personalized and decentralized diagnostic solutions.

Diverse Diagnostic Platforms

Anbio offers a diverse portfolio of mature diagnostic assays and five key platforms for biomarker detection:

• Fluorescent Immunochromatographic Solution (FIA)
• Chemiluminescent Immunoassay Solution (ChLIA)
• Polymerase Chain Reaction Solution (PCR)
• Lateral Flow Assay Solution (LFIA)
• Loop-Mediated Isothermal Amplification Solution (LAMP)

These platforms cater to point-of-care settings, laboratory use, and over-the-counter applications, providing healthcare providers and patients with fast, reliable, and cost-effective diagnostic tools.

Global Presence and Impact

With a strong presence across the European Union, Asia-Pacific, and the Americas, Anbio’s Conformité Européenne (CE)-marked products detect biomarkers associated with critical medical domains. These include infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes.

Commitment to Accessible Healthcare

Designed for compatibility with various sample collection matrices such as serum, plasma, whole blood, feces, urine, and saliva, Anbio’s product lineup facilitates efficient and reliable diagnostic testing across diverse patient populations and healthcare settings.

Looking Ahead

The successful IPO and Nasdaq listing position Anbio Biotechnology to enhance its contributions to global healthcare. As the company expands and innovates, it remains focused on its mission to provide accessible diagnostic solutions that meet the evolving needs of patients and healthcare providers worldwide.

For more information, please visit Anbio Biotechnology’s website.